These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 6090973

  • 21. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas.
    Hall WA, Doolittle ND, Daman M, Bruns PK, Muldoon L, Fortin D, Neuwelt EA.
    J Neurooncol; 2006 May; 77(3):279-84. PubMed ID: 16314949
    [Abstract] [Full Text] [Related]

  • 22. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
    Zylber-Katz E, Gomori JM, Schwartz A, Lossos A, Bokstein F, Siegal T.
    Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
    [Abstract] [Full Text] [Related]

  • 23. Osmotic blood-brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain.
    Neuwelt EA, Barnett PA, McCormick CI, Frenkel EP, Minna JD.
    Neurosurgery; 1985 Sep; 17(3):419-23. PubMed ID: 3930991
    [Abstract] [Full Text] [Related]

  • 24. [Intra-arterial infusion of high dose methotrexate therapy in recurrent gliomas].
    Hayashi A, Kyuma Y.
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1461-6. PubMed ID: 2117886
    [Abstract] [Full Text] [Related]

  • 25. Seizure-promoting effect of blood-brain barrier disruption.
    Marchi N, Angelov L, Masaryk T, Fazio V, Granata T, Hernandez N, Hallene K, Diglaw T, Franic L, Najm I, Janigro D.
    Epilepsia; 2007 Apr; 48(4):732-42. PubMed ID: 17319915
    [Abstract] [Full Text] [Related]

  • 26. Osmotic blood-brain barrier modification: clinical documentation by enhanced CT scanning and/or radionuclide brain scanning.
    Neuwelt EA, Specht HD, Howieson J, Haines JE, Bennett MJ, Hill SA, Frenkel EP.
    AJR Am J Roentgenol; 1983 Oct; 141(4):829-35. PubMed ID: 6412531
    [Abstract] [Full Text] [Related]

  • 27. Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy.
    Dahlborg SA, Henner WD, Crossen JR, Tableman CM, Petrillo A, Braziel R, Neuwelt EA.
    Cancer J Sci Am; 1996 Oct; 2(3):166-74. PubMed ID: 9166517
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
    Fortin D, Desjardins A, Benko A, Niyonsega T, Boudrias M.
    Cancer; 2005 Jun 15; 103(12):2606-15. PubMed ID: 15880378
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.
    Doolittle ND, Anderson CP, Bleyer WA, Cairncross JG, Cloughesy T, Eck SL, Guastadisegni P, Hall WA, Muldoon LL, Patel SJ, Peereboom D, Siegal T, Neuwelt EA.
    Neuro Oncol; 2001 Jan 15; 3(1):46-54. PubMed ID: 11305417
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [ACNU delivery to malignant glioma tissue by osmotic blood brain barrier modification with intracarotid infusion of hyperosmoral mannitol].
    Miyagami M, Kagawa Y, Tsubokawa T.
    No Shinkei Geka; 1985 Sep 15; 13(9):955-63. PubMed ID: 2999632
    [Abstract] [Full Text] [Related]

  • 35. Serum transthyretin monomer as a possible marker of blood-to-CSF barrier disruption.
    Marchi N, Fazio V, Cucullo L, Kight K, Masaryk T, Barnett G, Vogelbaum M, Kinter M, Rasmussen P, Mayberg MR, Janigro D.
    J Neurosci; 2003 Mar 01; 23(5):1949-55. PubMed ID: 12629200
    [Abstract] [Full Text] [Related]

  • 36. Effect of barrier opening on brain edema in human brain tumors.
    Sato S, Suga S, Yunoki K, Mihara B.
    Acta Neurochir Suppl (Wien); 1994 Mar 01; 60():116-8. PubMed ID: 7976519
    [Abstract] [Full Text] [Related]

  • 37. [Hemodynamic effects of an osmotic bolus for the reversible opening of the blood-brain barrier].
    Hiesmayr M, Dirnberger H, Aloy A, Heimberger K, Horaczek A, Brandstätter B, Zimpfer M.
    Schweiz Med Wochenschr; 1987 Mar 21; 117(12):450-4. PubMed ID: 3107120
    [Abstract] [Full Text] [Related]

  • 38. Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors.
    Neuwelt EA, Hill SA, Frenkel EP, Diehl JT, Maravilla KR, Vu LH, Clark WK, Rapoport SI, Barnett PA, Lewis SE, Ehle AL, Beyer CW.
    Cancer Treat Rep; 1981 Mar 21; 65 Suppl 2():39-43. PubMed ID: 6809316
    [Abstract] [Full Text] [Related]

  • 39. Testicular lymphoma, intraocular (vitreoretinal) lymphoma, and brain lymphoma: involvement of three immunoprivileged sites in one patient.
    Pe'er J, Rowe JM, Frenkel S, Dann EJ.
    Am J Hematol; 2010 Aug 21; 85(8):631-3. PubMed ID: 20658596
    [No Abstract] [Full Text] [Related]

  • 40. Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy.
    Korfel A, Thiel E.
    Leuk Lymphoma; 1998 Aug 21; 30(5-6):609-17. PubMed ID: 9711923
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.